{"id":"W4385612755","doi":"10.1016/j.jaad.2023.07.1024","title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Sanofi Genzyme; Celltrion; Eisai; Bristol-Myers Squibb; Samsung; AbbVie Canada; Coherus Biosciences; Mitsubishi Tanabe Pharma Corporation; Pfizer; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Dermira; Sun Pharma; Helsinn; Celgene; AbbVie; Sanofi; Amgen; Meiji Seika Pharma; EMD Serono; Galderma; Ortho Dermatologics; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Discontinuation; Adverse effect; Dermatology Life Quality Index; Internal medicine; Placebo; Randomized controlled trial; Severity of illness; Interim analysis; Surgery; Dermatology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01251768,0.001077147,0.002966797,0.0004362472,0.0005866208,0.001618042,0.0008674808,0.001418097,0.003173744],"category_scores_gemma":[0.006224034,0.000428268,0.004154823,0.0004193585,0.0006387669,0.001283288,0.0006512862,0.002618066,0.0006503211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005226523,"about_ca_system_score_gemma":0.001177962,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003269958,"about_ca_topic_score_gemma":0.0005333168,"domain_scores_codex":[0.9968989,0.001638474,0.0002136098,0.0003396091,0.0004455644,0.000463916],"domain_scores_gemma":[0.9945155,0.001696047,0.001660196,0.0008379632,0.0005173473,0.000772823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9322808,0.004731587,0.0210015,0.0005596266,0.004911155,0.0001421295,0.0001214425,0.001448113,0.003735644,0.0001572489,0.00256063,0.02835015],"study_design_scores_gemma":[0.4531156,0.3222747,0.1928346,0.0002776071,0.01574284,0.0005073347,0.0001274871,0.004191997,0.004988223,0.0008915987,0.004931674,0.0001162434],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855517,0.004692195,0.001331332,0.0004074306,0.0001700814,0.001154428,0.003577701,0.0001327792,0.002982282],"genre_scores_gemma":[0.9913607,0.0005778445,0.001009243,0.0004847037,0.0001574879,0.001159962,0.004114647,0.0000207528,0.001114507],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01251768,"threshold_uncertainty_score":0.06620061,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05163728112051134,"score_gpt":0.3408411507546446,"score_spread":0.2892038696341332,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}